1. ¹Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
2. ²Kinderklinik der Charité, Berlin, Germany
3. ³Division of Women's and Children's Services Bristol Royal Hospital for Children, Bristol, UK
4. ⁴Department of Hematology and Oncology, St Anna Children's Hospital, Vienna, Austria

Correspondence: Professor C Peters, Department of Hematology and Oncology, St Anna Children's Hospital, Kinderspitalgasse 6, Vienna A-1090, Austria. E-mail: Christina.peters@stanna.at

Abstract

The definition of indications for allogeneic SCT in children with high-risk (HR) ALL in the first remission or after the first or subsequent relapse depends on biological features, response to treatment and survival after chemotherapy alone. As the results of frontline and relapse protocols are improving over time, there is a strong need for prospective SCT trials, ensuring a well-standardized procedure regarding all relevant components that are potentially responsible for heterogeneity in post-SCT outcome. Therefore, in 2003, the ALL-BFM and the ALL-REZ BFM Study Group initiated a prospective, international, multicenter trial (ALL-SCT-BFM 2003). This trial will now be extended to a larger consortium, trial ALL-SCT-BFM-international (ALL-SCT-BFMi). Strict rules define HLA-typing, donor selection, conditioning regimen, GvHD prophylaxis and therapy as well as standards of supportive care to reduce treatment-related mortality and establish an early GVL effect. Moreover, comprehensive and closely reviewed documentation and serious adverse event reporting shall ensure high study quality. Case-by-case discussions of any fatal or critical course during annual meetings will improve the culture of failure management and lead to modifications of guidelines of supportive care. Finally, the results of these prospective trials will determine the current potential of the different SCT procedures in HR or relapsed childhood ALL.